Register for our free email digests:
Merck KGAA
www.emdgroup.com/en
Latest From Merck KGAA
Gene Therapy’s Next Big Challenge: Manufacturing
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.
Gene Therapy’s Next Big Challenge: Manufacturing
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.
EAGLE Crash Lands: AstraZeneca's Imfinzi/Tremelimumab Continues To Disappoint
The latest failure of the combination of AZ's PD-L1 inhibitor and its CLTA4 inhibitor is in advanced head and neck cancer. It follows recent failures of the MYSTIC and ARCTIC trials in lung cancer.
P&G's Personal Health Sector Has Merck Consumer Chief As International Head
P&G names Merck KGAA consumer chief Uta Kemmerich-Keil to lead international division of personal health business as it closes on $4.2bn acquisition of German firm's consumer business. Deal closes a month after P&G announced biggest changes to organizational structure in 20 years, including combining personal care and health care into personal health and forming six global units, each headed by a CEO.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Cardiovascular
- Gynecological, Urological
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
-
Merck KGAA
- Amerpharm Investments Ltd.
- Biovation Ltd.
- Center Laboratories
- Chemische Fabrik Lehrte Dr. Andreas Kossel
- Durachemie GMBH
- E. Merck Nederland
- EM Laboratories Inc
- EM Pharmaceuticals Inc.
- EMD Biosciences Inc.
- EMD Chemicals Inc.
- EMD Lexigen Research Center
- EMD Serono Inc.
- Genpharm Inc.
- Hermal Kurt Herrmann & Co.
- Hermal Pharmaceutical Laboratories Inc.
- Laboratoire Theramex
- Laboratoires Merck-Clevenot SA
- Laboratorios BOI SA
- Lipha Chemicals Inc.
- Lipha Pharmaceuticals Inc.
- Lipha SA
- Merck Eprova AG
- Merck Ethicals
- Merck HOEI
- Merck Lipha
- Merck Pty. Ltd.
- Merck SA Industrias Quimicas
- Merck Sante SAS
- Merck Serono SA
- MilliporeSigma
- Molteni Farmaceutici
- NM Pharma AS
- Novagen Inc.
- VWR Canlab
- Senior Management
-
Stefan Oschmann, PhD, CEO
Marcus Kuhnert, CFO - Contact Info
-
Merck KGAA
Phone: (49) 6151 72 0
Frankfurter Str. 250
Darmstadt, MA 64293
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice